Business Context and Reporting Period
This Form 8-K filing by vTv Therapeutics Inc. (Nasdaq: VTVT) reports a corporate event dated March 25, 2024. The Company is incorporated in Delaware and operates as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance status.
Material Changes
The primary event reported is the Company regaining compliance with Nasdaq Listing Rule 5550(b)(2). This rule requires a listed company's Market Value of Listed Securities (MVLS) to be at or above $35 million. Nasdaq confirmed that the Company's common stock listing on the Nasdaq Capital Market will continue.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies beyond the resolution of the specific listing deficiency regarding MVLS.
Investor Verification Checklist
- Verify the current Market Value of Listed Securities (MVLS) to ensure it remains above the $35 million threshold.
- Review the Company's recent stock price history to understand the volatility leading to the compliance regain.
- Check for any prior 8-K filings or Nasdaq deficiency notices related to MVLS to assess the duration of the non-compliance period.